Human immunodeficiency virus-specific T cell receptors

US12325734B2 · kind B2 · utility

Assignees

• Altor Bioscience LLC · US
• The USA, as represented by the Secretary, Dept. of Health and Human Services · US

Inventors

• Peter Rhode · Culver City, US
• Mark Connors · Bethesda, US
• Stephen Migueles · Washington, US

Key dates

• Filing date: Jan 15, 2020
• Grant date: Jun 10, 2025
• Expiry date: Oct 13, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Engineered TCR molecules specific to retroviral peptide/HLA complexes guide direct killing and/or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (Vα) domain, a TCR variable beta domain (Vβ) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.